Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial

Rationale: The combination of lumacaftor (LUM) and ivacaftor (IVA) is an approved CFTR (cystic fibrosis [CF] transmembrane conductance regulator) modulator treatment for homozygous F508del patients with CF. Objectives: To evaluate the effectiveness of LUM/IVA in children (6 yr or more) and adults (m...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Am Thorac Soc
Autors principals: Sagel, Scott D., Khan, Umer, Heltshe, Sonya L., Clancy, John P., Borowitz, Drucy, Gelfond, Daniel, Donaldson, Scott H., Moran, Antoinette, Ratjen, Felix, VanDalfsen, Jill M.
Format: Artigo
Idioma:Inglês
Publicat: American Thoracic Society 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7780982/
https://ncbi.nlm.nih.gov/pubmed/32644818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1513/AnnalsATS.202002-144OC
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars